McKesson Corporation J.P. Morgan Healthcare Conference

Similar documents
McKesson Corporation J.P. Morgan Healthcare Conference

McKesson Corporation Fiscal 2018 Financial Performance Fiscal 2019 Annual Outlook. Financial Results and Company Highlights May 24, 2018

McKESSON REPORTS FISCAL 2017 SECOND-QUARTER RESULTS AND REVISED FISCAL 2017 OUTLOOK

McKesson Corporation Q2 Fiscal 2019 Financial Performance. Financial Results and Company Highlights October 25, 2018

Bank of America Merrill Lynch 2013 Health Care Conference

McKESSON REPORTS FISCAL 2017 FOURTH-QUARTER AND FULL-YEAR RESULTS

McKESSON REPORTS FISCAL 2017 FIRST-QUARTER RESULTS

McKESSON REPORTS FISCAL 2018 THIRD-QUARTER RESULTS

McKESSON REPORTS FISCAL 2015 SECOND-QUARTER RESULTS

McKESSON REPORTS FISCAL 2013 SECOND-QUARTER RESULTS

McKESSON REPORTS FISCAL 2016 SECOND-QUARTER RESULTS

McKESSON REPORTS FISCAL 2015 THIRD-QUARTER RESULTS

McKesson Reports Fiscal 2017 Fourth-Quarter and Full-Year Results

34 th Annual J.P. Morgan Healthcare Conference. Steve Collis, President & CEO Tim Guttman, EVP & CFO

McKESSON REPORTS FISCAL 2016 FIRST-QUARTER RESULTS

McKESSON REPORTS FISCAL 2018 SECOND-QUARTER RESULTS

McKESSON REPORTS FISCAL 2012 SECOND-QUARTER RESULTS

McKESSON REPORTS FISCAL 2019 SECOND-QUARTER RESULTS

RITE AID REPORTS NET INCOME OF $127.8 MILLION AND ADJUSTED EBITDA OF $364.2 MILLION FOR SECOND QUARTER FISCAL 2015

Fiscal 2018 Third Quarter Results. 28 June 2018

Standing strong for payers and patients

2009 UBS Healthcare Services Conference

RITE AID REPORTS NET INCOME AND RECORD ADJUSTED EBITDA FOR FOURTH QUARTER AND FULL 2014 FISCAL YEAR

Fiscal 2017 First Quarter Results. 5 January 2017

Safe harbor and non-gaap

Walgreens Boots Alliance 3Q16 Consolidated Financial Results Earnings conference call. 6 July 2016

Walgreens Boots Alliance Reports Fiscal 2019 First Quarter Results Delivers Double Digit Percentage Growth in Earnings Per Share (EPS)

Walgreens Boots Alliance 2015 analyst meeting financial session. Safe Harbor and Non-GAAP

Brian Bertha VP, Corporate Strategy and Business Development McKesson U.S. Pharmaceutical

Walgreens Boots Alliance Reports Fiscal 2018 Second Quarter Results

Walgreens Boots Alliance Reports Fiscal 2016 Third Quarter Results

Walgreens Boots Alliance Reports Fourth Quarter and Fiscal 2016 Results

Fourth Quarter and Fiscal 2016 Results. 20 October 2016

Walgreens Boots Alliance Reports Fiscal 2015 Year-End and Fourth Quarter Results

CIGNA AND EXPRESS SCRIPTS: EXPANDS GROWTH OPPORTUNITIES IMPROVES AFFORDABILITY CREATES DIFFERENTIATED SHAREHOLDER VALUE

Fourth Quarter and Fiscal 2018 Results. October 11, 2018

Walgreens Boots Alliance Reports Fourth Quarter and Fiscal 2017 Results

Fiscal 2019 First Quarter Results. December 20, 2018

McKesson Corporation 2013 Investor Day. June 26, 2013

Walgreens Boots Alliance Reports Fiscal 2018 Third Quarter Results

Standing strong for payers and patients

Puma Biotechnology 3Q Earnings Call Commercial Update

Walgreens Boots Alliance Reports Fiscal 2017 First Quarter Results

PERFORMANCE AND TRAJECTORY

McKesson Reports Fiscal 2018 Second-Quarter Results

Walgreen Co. Reports Fiscal 2014 Second Quarter Results

Walgreens Boots Alliance Reports Fiscal 2018 First Quarter Results

J.P. Morgan Healthcare Conference

Waters Corporation Management Presentation

Walgreens Boots Alliance Reports Fiscal 2016 Second Quarter Results

Walgreens Boots Alliance Fiscal year end 2015 and 4Q earnings conference call. 28 October 2015

Rent-A-Center today is

Waters Corporation Management Presentation. July 2018

Zimmer Biomet Reports Second Quarter 2016 Financial Results

DJO Global, Inc. Company Presentation. June 2013

McKESSON AND CHANGE HEALTHCARE COMPLETE THE CREATION OF NEW HEALTHCARE INFORMATION TECHNOLOGY COMPANY. New Company Is Named Change Healthcare

First-Quarter 2018 Earnings

Q4 AND FULL YEAR 2017 UPDATE. March 1, 2018

36 th Annual J.P. Morgan Healthcare Conference. January 10, 2018

Walgreen Co. Reports Fiscal 2012 Third Quarter Earnings of $537 Million, or 62 Cents per Diluted Share

FULL YEAR 2018 PRESS CONFERENCE FEBRUARY 20, Rice Powell CEO. Copyright

Walgreen Co. Reports Fiscal 2013 First Quarter Results

Healthcare is changing We re changing healthcare. George S. Barrett Chairman and Chief Executive Officer

Walgreens-Alliance Boots Investor Call

SAFE HARBOR STATEMENT

SAFE HARBOR STATEMENT

Dave Carlucci Chairman and CEO IMS Health

Safe Harbor Statement

Increasing Shareholder Value Wayne DeVeydt EVP & Chief Financial Officer

36th Annual J.P. Morgan Healthcare Conference

HEADLINE: Streamline Health(R) Reports Third Quarter 2018 Revenues of $5.4 Million; ($0.7 Million) Net Loss; Adjusted EBITDA of $0.

Baird 2018 Global Healthcare Conference. September 5, 2018

Q Earnings Call

Cowen and Company 38 th Annual Health Care Conference. March 13, 2018

UNIQUELY POSITIONED FOR THE FUTURE

Diplomat Announces 4th Quarter and 2017 Year End Financial Results; Provides 2018 Guidance

Fourth Quarter and Full Year 2017 Results Conference Call. March 9, 2018

Fourth Quarter 2017 Earnings Conference Call

Fiscal Year 2011 Core Strategies and Milestones Express Scripts Update

33rd Annual J.P. Morgan Healthcare Conference. Bill Lucia, Chief Executive Officer January 14, 2015

FINANCIAL HIGHLIGHTS. Sales

2017 WELLS FARGO HEALTHCARE CONFERENCE

Jefferies 2017 Health Care Conference

Third Quarter 2018 Results Conference Call. November 7, 2018

3 rd Quarter Fiscal 2019

Express Scripts Announces 2017 Third Quarter Results

West Pharmaceutical Services, Inc. June 2016

Endo International plc

SAFE HARBOR STATEMENT

Puma Biotechnology Earnings Call Commercial Update

June Investor Presentation

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K

J.P. MORGAN HEALTHCARE CONFERENCE. Joe Woody Chief Executive Officer

Investor Mike McGuire Media Carolyn Castel Contact: Senior Vice President Contact: Vice President (401) (401) FOR IMMEDIATE RELEASE

JUNE 19, Creating The First Global Pharmacy-Led Health & Wellbeing Enterprise

Safe Harbor Statement

Raymond James 37 th Annual Institutional Investors Conference. March 8, 2016

INVESTOR PRESENTATION MAY 2017

R1 RCM Inc. (Exact Name of Registrant as Specified in Charter)

Q4 and Full Year 2018 Earnings Call

Transcription:

McKesson Corporation J.P. Morgan Healthcare Conference John Hammergren Chairman and Chief Executive Officer

Forward-Looking Statements Some of the information in this presentation is not historical in nature and may constitute forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking terminology such as believes, expects, anticipates, may, will, should, seeks, approximately, intends, plans, estimates, or the negative of these words or other comparable terminology. The discussion of financial trends, strategy, plans or intentions may also include forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied by such statements. Although it is not possible to predict or identify all such risks and uncertainties, they may include, but are not limited to, those described in the Company s annual, quarterly and current reports (i.e., Form 10-K, Form 10-Q and Form 8-K) as filed or furnished with the Securities and Exchange Commission (SEC). You are cautioned not to place undue reliance on any such forward-looking statements, which speak only as of the date such statements were first made. To the degree financial information is included in this presentation, it is in summary form only and must be considered in the context of the full details provided in the Company s most recent annual, quarterly or current report as filed or furnished with the SEC. The Company s SEC reports are available at www.mckesson.com under the Investors tab. Except to the extent required by law, the Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events. GAAP / Non-GAAP Reconciliation In an effort to provide additional and useful information regarding the Company s financial results and other financial information as determined by generally accepted accounting principles (GAAP), certain materials in this presentation include non-gaap information. McKesson also presents its financial results on a constant currency basis. The Company conducts business worldwide in local currencies, including Euro, British pound and Canadian dollar. As a result, the comparability of the financial results reported in U.S. dollars can be affected by changes in foreign currency exchange rates. The Company believes the presentation of non-gaap measures provides useful supplemental information to investors with regard to its core operating performance as well as comparability of financial results period-over-period. A reconciliation of the non-gaap information to GAAP, and other related information is available in the tables accompanying each period s earnings press release, materials furnished to the SEC, and posted to www.mckesson.com under the Investors tab. 2

Today s Discussion McKesson At A Glance Business Overview Key Strategies Near-term Challenges Financial Drivers 3

McKesson At A Glance Delivering Better Health to All >180 year history of serving customers $100B Sep-16 YTD revenues $2.9B Sep-16 YTD operating cash flow Delivering 75,ooo+ More than 13,000 owned and banner pharmacies 1/3 employees worldwide of all prescription medicine in North America >99% order accuracy Financial data reported for Fiscal Year as of September 30, 2016; Operational and employee data reflected as of December 31, 2016. 4

Business Overview DISTRIBUTION SOLUTIONS North America Pharmaceutical Distribution and Services Medical-Surgical Distribution and Services International Pharmaceutical Distribution and Services Technology Solutions Supplies branded, specialty, generic pharmaceuticals to pharmacies, health systems; retail operations in Canada Provides medical surgical supplies to non-acute care settings in the U.S. Provides pharmaceutical distribution and retail operations in Europe Delivers enterprisewide technology solutions to healthcare organizations World-Class Global Procurement and Sourcing 5

Unlocking Value Of Technology Businesses McKesson Technology Solutions Enhances MTS market opportunity, capabilities and scale Strong partnership, with focus on value creation McKesson to receive $1.25 billion in cash at close of transaction, retaining ~70% equity stake Targeting $150+ million of annual synergies, with potential to capture more 6

Leading Global Sourcing Capabilities Global footprint of combined distribution & pharmacy operations Highlights Enterprise-wide global procurement and sourcing Robust private-label capabilities, driving value and opportunities for expansion Global procurement and sourcing operations Co-sourcing partnership with Walmart, ClarusONE Sourcing Solutions LLP, operational in late Fiscal 2017 7

Increasing Opportunities in Specialty Providers Expanded and enhancing manufacturer services Manufacturers Differentiated and growing physician offerings 3,400+ oncologists 5,000+ other specialists Payers Patients Spanning a drug s life cycle from clinical trials to distribution McKesson Specialty Health data as of September 30, 2016. 8

Innovating And Expanding in Retail A Global Footprint 13,000+ owned and banner pharmacies globally United States: More than 4,700 Health Mart stores Canada: More than 2,500 owned and banner pharmacies Europe: More than 6,500 owned and banner pharmacies Broad Service Offerings Payer access and programs for independent pharmacies Patient adherence and claims management Automated pharmacy solution statistics Reimbursement optimization European Pharmacy Network Market data as of December 31, 2016. 9

Though McKesson Is Facing Near-Term Challenges Fewer expected generic launches compared to prior years Moderation of brand and generic pharmaceutical pricing trends Increase in customer pricing competitiveness Impact of customer consolidation 10

Our Strong Value Proposition Positions Us For Long-Term Growth Well-positioned businesses Operational excellence Customer-first focus Experienced management team Disciplined capital deployment Pathway to Double-Digit Earnings* Growth * Earnings refers to non-gaap earnings per diluted share. 11